Onfekafusp alfa
- Generic Name
- Onfekafusp alfa
- Drug Type
- Biotech
- CAS Number
- 1957239-88-1
- Unique Ingredient Identifier
- 6HXC0O6JMV
- Background
Onfekafusp alfa is under investigation in clinical trial NCT02938299 (Neoadjuvant L19IL2/L19TNF- Pivotal Study).
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Philogen S.p.A.
- Registration Number
- NCT05304663
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Phase 2
Active, not recruiting
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Philogen S.p.A.
- Target Recruit Count
- 98
- Registration Number
- NCT04733183
- Locations
- 🇫🇷
Hopital Jean Minjoz, Besançon, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Philogen S.p.A.
- Target Recruit Count
- 102
- Registration Number
- NCT04650984
- Locations
- 🇪🇸
Hospital General Universitario Gregorio Marañón, Madrid, Spain
🇪🇸Fundación Jiménez Díaz, Madrid, Spain
🇪🇸Hospital Universitario Virgen de las Nieves, Granada, Spain
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Philogen S.p.A.
- Target Recruit Count
- 226
- Registration Number
- NCT04443010
- Locations
- 🇨🇭
UniversitatSpital USZ, Zürich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath